Previously, ECH1 has been confirmed to mitigate HFD-induced IR and hepatic steatosis directly by restraining the expression of lipogenesis genes and by repressing the insulin pathway via the attenuation of Akt phosphorylation (144). Here, ECH1 is linked to fatty liver disease.